Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients

International Journal of Cancer

Volumn 137, Issue 5, 2015, Pages 1095-1106

  Jia, Yunlong ^a   Wang, Hongyan ^a   Wang, Yu ^a   Wang, Tingting ^a   Wang, Miao ^a   Ma, Ming ^a   Duan, Yuqing ^a   Meng, Xianli ^a   Liu, Lihua ^a,b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

bridging integrator 1 (Bin1); esophageal squamous cell cancer (ESCC); immuno editing; indoleamine 2,3 dioxygenase (IDO); prognosis

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; BIN1 PROTEIN, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; NUCLEAR PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; ADULT; AGED; ESOPHAGUS TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE; LYMPH NODE METASTASIS; LYMPHOCYTE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR MICROENVIRONMENT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOCYTES; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEINS;

EID: 84931565948     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29481     Document Type: Article

References (45)

1. Ferlay J, Shin HR, Bray F, et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Jemal A, Bray F, Center MM, et al., Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
3. Zhu CM, Ling YH, Xi SY, et al., Prognostic significance of the pN classification supplemented by vascular invasion for esophageal squamous cell carcinoma. PloS One 2014; 9: e96129.
4. Pennathur A, Gibson MK, Jobe BA, et al., Oesophageal carcinoma. Lancet 2013; 381: 400-12.
5. Dunn GP, Bruce AT, Ikeda H, et al., Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
6. Sounni NE, Noel A,. Targeting the tumor microenvironment for cancer therapy. Clin Biochem 2013; 59: 85-93.
7. Protti MP, Monte LD, Lullo GD,. Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies. Tissue Antigens 2014; 83: 237-46.
8. Hanahan D, Weinberg RA,. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
9. Hugues S, Fetler L, Bonifaz L, et al., Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 2004; 5: 1235-42.
10. Park YJ, Song B, Kim YS, et al., Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells. Cancer Res 2013; 73: 5669-81.
11. Lund AW, Duraes FV, Hirosue S, et al., VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 2012; 1: 191-9.
12. Baitsch L, Baumgaertner P, Devêvre E, et al., Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest 2011; 121: 2350.
13. Fattorossi A, Battaglia A, Ferrandina G, et al., Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer 2004; 100: 1418-28.
14. Jalili RB, Forouzandeh F, Moeenrezakhanlou A, et al., Mouse pancreatic islets are resistant to indoleamine 2,3 dioxygenase-induced general control nonderepressible-2 kinase stress pathway and maintain normal viability and function. Am J Pathol 2009; 174: 196-205.
15. Sato N, Saga Y, Mizukami H, et al., Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation. Oncol Rep 2012; 28: 1574-8.
16. de Jong RA, Kema IP, Boerma A, et al., Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. Gynecol Oncol 2012; 126: 474-80.
17. Novitskiy SV, Moses HL,. Turn off the IDO: will clinical trials be successful? Cancer Discov 2012; 2: 673-5.
18. Munn DH,. Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed) 2012; 4: 734-45.
19. Terme M, Pernot S, Marcheteau E, et al., VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013; 73: 539-49.
20. Cassimere EK, Pyndiah S, Sakamuro D,. The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage. Cell Death Differ 2009; 16: 1641-53.
21. Muller AJ, DuHadaway JB, Donover PS, et al., Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11: 312-9.
22. Sakamuro D, Elliott KJ, Wechsler-Reya R, et al., BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet 1996; 14: 69-77.
23. Pyndiah S, Tanida S, Ahmed KM, et al., cMYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal 2011; 4: ra19.
24. Pan K, Liang XT, Zhang HK, et al., Characterization of bridging integrator 1 (BIN1) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma. Mol Med 2012; 18: 50718.
25. Zhang G, Liu WL, Zhang L, et al., Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma. Clin Dev Immunol 2011; 2011: 384726.
26. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods (San Diego, Calif) 2001; 25: 402-8.
27. Gao YF, Peng RQ, Li J, et al., The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med 2009; 7: 71.
28. Napier KJ, Scheerer M, Misra S,. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 2014; 6: 112-20.
29. Bordon E, Henriquez-Hernandez LA, Lara PC, et al., Role of CD4 and CD8 T-lymphocytes, B-lymphocytes and natural killer cells in the prediction of radiation-induced late toxicity in cervical cancer patients. Int J Radiat Biol 2011; 87: 424-31.
30. Fujii H, Arakawa A, Utsumi D, et al., CD8(+) tumor-infiltrating lymphocytes at primary sites as a possible prognostic factor of cutaneous angiosarcoma. Int J Cancer 2014; 134: 2393-402.
31. Stojanovic A, Cerwenka A,. Natural killer cells and solid tumors. J Innate Immun 2011; 3: 355-64.
32. Natarajan P, Singh A, McNamara JT, et al., Regulatory B cells from hilar lymph nodes of tolerant mice in a murine model of allergic airway disease are CD5+, express TGF-beta, and co-localize with CD4+Foxp3+ T cells. Mucosal Immunol 2012; 5: 691-701.
33. Ruddell A, Harrell MI, Furuya M, et al., B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma. Neoplasia 2011; 13: 748-57.
34. Bilate AM, Lafaille JJ,. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol 2012; 30: 733-58.
35. Uyttenhove C, Pilotte L, Theate I, et al., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9: 1269-74.
36. Mellor AL, Munn DH,. Physiologic control of the functional status of Foxp3+ regulatory T cells. J Immunol 2011; 186: 4535-40.
37. Sharma MD, Hou DY, Liu Y, et al., Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009; 113: 6102-11.
38. DuHadaway JB, Sakamuro D, Ewert DL, et al., Bin1 mediates apoptosis by c-myc in transformed primary cells. Cancer Res 2001; 61: 3151-6.
39. Ge K, Minhas F, Duhadaway J, et al., Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer 2000; 86: 155-61.
40. Barekati Z, Radpour R, Lu Q, et al., Methylation signature of lymph node metastases in breast cancer patients. BMC Cancer 2012; 12: 244.
41. Tanida S, Mizoshita T, Ozeki K, et al., Mechanisms of Cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol 2012; 2012: 862879.
42. Muller AJ, Duhadaway JB, Sutanto-Ward E, et al., Transcriptional control of IDO by the cancer suppression gene Bin1, a key mechanism for restraining tumor immune escape. P Assoc Am Phys 2005; 2005: 1255.
43. DuHadaway JB, Lynch FJ, Brisbay S, et al., Immunohistochemical analysis of Bin1/amphiphysin II in human tissues: diverse sites of nuclear expression and losses in prostate cancer. J Cell Biochem 2003; 88: 635-42.
44. Sakurai K, Enomoto K, Amano S, et al., Study of indoleamine 2,3-dioxygenase expression in patients of esophageal squamous cell carcinoma. Gan Kagaku Ryoho Cancer Chemother 2004; 31: 1780-2.
45. Liu J, Lu G, Tang F, et al., Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas. Virch Arch 2009; 455: 441-8.